Search Results - "Kabbinavar, F"

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial by Colevas, A.D., Bahleda, R., Braiteh, F., Balmanoukian, A., Brana, I., Chau, N.G., Sarkar, I., Molinero, L., Grossman, W., Kabbinavar, F., Fassò, M., O’Hear, C., Powderly, J.

“…Head and neck cancer (HNC) has a poor prognosis at advanced stages. Given the immunosuppressive tumor microenvironment in HNC, inhibition of the programmed…”
Get full text

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial by Mansfield, A.S., Każarnowicz, A., Karaseva, N., Sánchez, A., De Boer, R., Andric, Z., Reck, M., Atagi, S., Lee, J.-S., Garassino, M., Liu, S.V., Horn, L., Wen, X., Quach, C., Yu, W., Kabbinavar, F., Lam, S., Morris, S., Califano, R.

“…The addition of atezolizumab to carboplatin and etoposide (CP/ET) significantly improved progression-free and overall survival for patients with…”
Get full text

Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer by KABBINAVAR, Fairooz F, HAMBLETON, Julie, MASS, Robert D, HURWITZ, Herbert I, BERGSLAND, Emily, SARKAR, Somnath

“…Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that…”
Get full text

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005 by Ji, Yongli, Rankin, Cathryn, Grunberg, Steven, Sherrod, Andy E, Ahmadi, Jamshid, Townsend, Jeannette J, Feun, Lynn G, Fredericks, Ruth K, Russell, Christy A, Kabbinavar, Fairooz F, Stelzer, Keith J, Schott, Anne, Verschraegen, Claire

“…Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in…”
Get full text

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial by KABBINAVAR, Fairooz F, SCHULZ, Joseph, MCCLEOD, Michael, PATEL, Taral, HAMM, John T, HECHT, J. Randolph, MASS, Robert, PERROU, Brent, NELSON, Betty, NOVOTNY, William F

“…Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in…”
Get full text

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials by KABBINAVAR, Fairooz F, HURWITZ, Herbert I, JING YI, SARKAR, Somnath, ROSEN, Oliver

“…Colorectal cancer (CRC) occurs predominantly in older persons. To provide more statistical power to assess risk/benefit in older patients, we examined the…”
Get full text

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database by Shi, Qian, de Gramont, Aimery, Grothey, Axel, Zalcberg, John, Chibaudel, Benoist, Schmoll, Hans-Joachim, Seymour, Matthew T, Adams, Richard, Saltz, Leonard, Goldberg, Richard M, Punt, Cornelis J A, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Porschen, Rainer, Tebbutt, Niall C, Fuchs, Charles, Souglakos, John, Falcone, Alfredo, Tournigand, Christophe, Kabbinavar, Fairooz F, Heinemann, Volker, Van Cutsem, Eric, Bokemeyer, Carsten, Buyse, Marc, Sargent, Daniel J

“…Progression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC)…”
Get full text

Randomized Phase II Study of Erlotinib Combined With Bevacizumab Compared With Bevacizumab Alone in Metastatic Renal Cell Cancer by BUKOWSKI, Ronald M, KABBINAVAR, Fairooz F, SCAPPATICCI, Frank A, MCDERMOTT, David, FIGLIN, Robert A, FLAHERTY, Keith, SRINIVAS, Sandy, VAISHAMPAYAN, Ulka, DRABKIN, Harry A, DUTCHER, Janice, RYBA, Sarah, QI XIA

“…Bevacizumab (Bev) has clinical activity in advanced renal cell carcinoma (RCC), and, when combined with erlotinib (Erl), has shown encouraging objective…”
Get full text

Cytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma by KLATTE, Tobias, NAGESH RAO, P, DE MARTINO, Michela, LAROCHELLE, Jeffrey, SHUCH, Brian, ZOMORODIAN, Nazy, SAID, Jonathan, KABBINAVAR, Fairooz F, BELLDEGRUN, Arie S, PANTUCK, Allan J

“…The majority of cytogenetic studies in renal cell carcinoma (RCC) have been impaired by small sample size, retrospective character, and lack of a survival end…”
Get full text

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database by Renfro, Lindsay A, Goldberg, Richard M, Grothey, Axel, Sobrero, Alberto, Adams, Richard, Seymour, Matthew T, Heinemann, Volker, Schmoll, Hans-Joachim, Douillard, Jean-Yves, Hurwitz, Herbert, Fuchs, Charles S, Diaz-Rubio, Eduardo, Porschen, Rainer, Tournigand, Christophe, Chibaudel, Benoist, Hoff, Paulo M, Kabbinavar, Fairooz F, Falcone, Alfredo, Tebbutt, Niall C, Punt, Cornelis J A, Hecht, J Randolph, Souglakos, John, Bokemeyer, Carsten, Van Cutsem, Eric, Saltz, Leonard, de Gramont, Aimery, Sargent, Daniel J

“…Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data…”
Get full text

Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy by KLATTE, Tobias, SELIGSON, David B, LAROCHELLE, Jeffrey, SHUCH, Brian, SAID, Jonathan W, RIGGS, Stephen B, ZOMORODIAN, Nazy, KABBINAVAR, Fairooz F, PANTUCK, Allan J, BELLDEGRUN, Arie S

“…Purpose: To identify the molecular signature of localized (N0M0) clear cell renal cell carcinoma (RCC) and assess its ability to predict outcome. Methods:…”
Get full text

Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma by KLATTE, Tobias, PANTUCK, Allan J, SAID, Jonathan W, SELIGSON, David B, RAO, Nagesh P, LAROCHELLE, Jeffrey C, SHUCH, Brian, ZISMAN, Amnon, KABBINAVAR, Fairooz F, BELLDEGRUN, Arie S

“…Purpose: The goal of this study was to evaluate immunohistochemical and cytogenetic features and their prognostic value in papillary renal cell carcinoma…”
Get full text

Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma by Klatte, Tobias, Seligson, David B, Riggs, Stephen B, Leppert, John T, Berkman, Maria K, Kleid, Mark D, Yu, Hong, Kabbinavar, Fairooz F, Pantuck, Allan J, Belldegrun, Arie S

“…Purpose: Hypoxia-inducible factor-1α (HIF-1α) plays an important role in tumoral adaptation to hypoxic conditions by serving as a transcription factor for…”
Get full text

Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm by Shuch, Brian, Riggs, Stephen B., LaRochelle, Jeff C., Kabbinavar, Fairooz F., Avakian, Raffi, Pantuck, Allan J., Patard, Jean‐Jacques, Belldegrun, Arie S.

“…OBJECTIVE To evaluate our early experience with neoadjuvant therapy (sunitinib or sorafenib) in advanced renal cell carcinoma (RCC), to explore the effect on…”
Get full text

Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium by Sweeney, Christopher J, Roth, Bruce J, Kabbinavar, Fairooz F, Vaughn, David J, Arning, Michael, Curiel, Rafael E, Obasaju, Coleman K, Wang, Yanping, Nicol, Steven J, Kaufman, Donald S

“…To assess the antitumor activity and toxicity of pemetrexed as second-line chemotherapy in patients with locally advanced or metastatic transitional cell…”
Get full text

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma by Fishman, M.N, Srinivas, S, Hauke, R.J, Amato, R.J, Esteves, B, Cotreau, M.M, Strahs, A.L, Slichenmyer, W.J, Bhargava, P, Kabbinavar, F.F

“…Abstract Background Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, with a…”
Get full text

IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) by Haddad, R., Wong, D.J., Guo, Y., Fayette, J., Cohen, E.E.W., Kowgier, M., Sandler, A., Matheny, C., Kabbinavar, F., Raben, D.

Get full text

IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) by Mok, T.S.K., Reck, M., Horn, L., Lam, S., Shames, D.S., Liu, J., Kabbinavar, F., Lin, W., Sandler, A., Liu, S.V.

Get full text

Smoking negatively impacts renal cell carcinoma overall and cancer‐specific survival by Kroeger, Nils, Klatte, Tobias, Birkhäuser, Frédéric D., Rampersaud, Edward N., Seligson, David B., Zomorodian, Nazy, Kabbinavar, Fairooz F., Belldegrun, Arie S., Pantuck, Allan J.

“…BACKGROUND: Tobacco use is a leading cause of premature death, yet few studies have investigated the effect of tobacco exposure on the outcome of patients with…”
Get full text

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project by Sjoquist, Katrin M, Renfro, Lindsay A, Simes, R John, Tebbutt, Niall C, Clarke, Stephen, Seymour, Matthew T, Adams, Richard, Maughan, Timothy S, Saltz, Leonard, Goldberg, Richard M, Schmoll, Hans-Joachim, Van Cutsem, Eric, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Tournigand, Christophe, Punt, Cornelis J A, Koopman, Miriam, Hurwitz, Herbert, Heinemann, Volker, Falcone, Alfredo, Porschen, Rainer, Fuchs, Charles, Diaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Souglakos, Ioannis, Kabbinavar, Fairooz F, Chibaudel, Benoist, Meyers, Jeffrey P, Sargent, Daniel J, de Gramont, Aimery, Zalcberg, John R

“…Abstract Background Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical…”
Get full text